TRICARE Prior Authorization Request Form for netarsudil 0.02% ophthalmic solution (Rhopressa), netarsudil/latanoprost ophthalmic solution (Rocklatan)



USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider		
Drug Name:	Strength:	
Dosage/Frequency (SIG):	Duration of Therapy:	

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

HEALTHCARE 7231 Parkway Drive, Suite 100, Hanover, MD 21076

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):		
1	Patient Name: F	Physician Name:	
	Address:	Address:	
	Sponsor ID #	Phone #:	
<u> </u>	Date of Birth:	Secure Fax #:	
Step	Please complete the clinical assessment:		
2	 Does the patient have a diagnosis of ocular hypertension or open-angle glaucoma? 	□ Yes	🗆 No
		Proceed to question 2	STOP
			Coverage not approved
	2. Is the prescription written by an ophthalmologist or an optometrist?	□ Yes	🗆 No
		Proceed to question 3	STOP
			Coverage not approved
	3. Will the patient be using both Rhopressa and Rocklatan	□ Yes	□ No
	at the same time?	STOP	Proceed to question 4
		Coverage not approved	
	4. Has the patient had a trial of appropriate duration with	□ Yes	□ No
	two different formulary options, from any of the following different glaucoma drug classes, in	Proceed to question 5	STOP
	combination or separately: prostaglandin analogs (latanoprost or bimatoprost), beta blockers (Betoptic, Betoptic-S, Ocupress, Betagan, Optipranolol), alpha2- adrenergic agonists (brimonidine, apraclonidine), topical carbonic anhydrase inhibitors (dorzolamide (Trusopt)?		Coverage not approved

TRICARE Prior Authorization Request Form for netarsudil 0.02% ophthalmic solution (Rhopressa), netarsudil/latanoprost ophthalmic solution (Rocklatan)

. Has the patient reached intraocular pressure target	□ Yes	□ No
goals using medications from standard therapy classes as defined by provider? (standard therapy	STOP	Sign and date below
classes include: prostaglandin analogs (latanoprost or bimatoprost), beta blockers (Betoptic, Betoptic-S, Ocupress, Betagan, Optipranolol), alpha2-adrenergic agonists (brimonidine, apraclonidine), topical carbonic anhydrase inhibitors (dorzolamide (Trusopt).	Coverage not approved	

Step	I certify the above is true to the best of my knowledge.	Please sign and date:
3		

Prescriber Signature

Date

[23 May 2019]

For Internal Use Only	
Approved:	Duration of Approval:month(s)
Denied:	Authorized By:
Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: